ID   RB355 CDDP-R
AC   CVCL_B7IH
SY   RB-355 cisplatin-resistant; RB-355 CisPt
DR   Wikidata; Q114312769
RX   PubMed=29192327;
CC   Problematic cell line: Contaminated. Parent cell line (RB355) has been shown to be a Y-79 derivative.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; HGNC:9884; RB1; Unexplicit; Ex2-6del; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9884; RB1; Unexplicit; IVS20+1G>A; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Eye, globe; UBERON=UBERON_0010230.
DI   NCIt; C7541; Retinoblastoma
DI   ORDO; Orphanet_790; Retinoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_S611 ! RB355
SX   Female
AG   2Y6M
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 19-12-24; Version: 5
//
RX   PubMed=29192327; DOI=10.3892/or.2017.6100; PMCID=PMC5783599;
RA   Busch, Maike Anna
RA   Papior, David
RA   Stephan, Harald
RA   Dunker, Nicole
RT   "Characterization of etoposide- and cisplatin-chemoresistant
RT   retinoblastoma cell lines.";
RL   Oncol. Rep. 39:160-172(2018).
//